GeneSparkDx – COVID 19

GeneSparkDX–SARS-CoV-2

In response to the COVID-19 pandemic, GeneSpark is developing a rapid and point-of-care molecular diagnostic assay with a simple workflow utilizing GeneSpark's portable GeneSparkDX instrument. GeneSparkDX–SARS-CoV-2 assay will use a nasopharyngeal swab sample specimen and has an analytic sensitivity of 250 copies of viral RNA/ml.

The reaction takes approximately 30 minutes. GeneSpark's rapid and easy-to-use test has applications in various point-of-care locations, including remote and rural areas. ​

Real-Time Reporting

GeneSpark's partnership with LabWare enables real-time reporting to the Public Health Laboratories and patients through LabWare's cloud-based Laboratory Information Management System (LIMS). GeneSparkDX, together with LabWare's Portable Disease Surveillance Lab kit, enables patient information collection, testing, and reporting in field locations with a seamless workflow.

The collaboration will significantly shorten the results turnaround time by days, effectively contain the virus's spread, and greatly improve surveillance programs.

Patient information collected

Allowing triage, sample routing, and distribution of results

Automated amplification

Detecting viral RNA targets and reporting results in 30 minutes